Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: Rationale, clinical experience, and future directions

Breast Cancer: Basic and Clinical Research

Volumn 7, Issue 1, 2013, Pages 7-22

  Yardley, Denise A ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Advanced breast cancer; HER2; Hormone receptor; mTOR

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DALOTUZUMAB; DOCETAXEL; EPIRUBICIN; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; FULVESTRANT; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVELBINE; NERATINIB; PACLITAXEL; PLACEBO; RAPAMYCIN; RIDAFOROLIMUS; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; XL 147; XL 765;

ANEMIA; ANOREXIA; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DYSLIPIDEMIA; DYSPNEA; ENZYME INHIBITION; FATIGUE; FEVER; HUMAN; HYPERGLYCEMIA; INFECTION; KIDNEY CARCINOMA; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; PNEUMONIA; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; TREATMENT OUTCOME;

EID: 84874217042     PISSN: 11782234     EISSN: None     Source Type: Journal    
DOI: 10.4137/BCBCR.S10071     Document Type: Review

References (87)

1. Colozza M, De Azambuja E, Cardoso F, et al. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist. 2006;11(2):111-25.
2. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010;28(20):3366-79.
3. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471-84.
4. Albanell J, Dalmases A, Rovira A, et al. mTOR signalling in human cancer. Clin Transl Oncol. 2007;9(8):484-93.
5. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5(8):671-88.
6. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010;20(1):87-90.
7. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4(5):335-48.
8. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926-45.
9. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004;3(8): 772-5.
10. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer. 2002;86(4):540-5.
11. Whenham N, D'Hondt V, Piccart MJ. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer. 2008; 8(1):38-49.
12. Carraway H, Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res. 2004; 6(5):219-4.
13. Lane HA, Lebwohl D. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (everolimus)-letrozole clinical program. Semin Oncol. 2006;33(2 Suppl 7):S18-25.
14. Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res. 2000;2(5):335-44.
15. Klos KS, Wyszomierski SL, Sun M, et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res. 2006;66(4): 2028-37.
16. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22(14):2954-63.
17. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3(10):1221-4.
18. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27(13):2278-87.
19. Di Cosimo S, Baselga J. Targeted therapies in breast cancer: where are we now? Eur J Cancer. 2008;44(18):2781-90.
20. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395-402.
21. Bartucci M, Morelli C, Mauro L, et al. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res. 2001;61(18):6747-54.
22. Zhou X, Tan M, Stone H, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res. 2004;10(20):6779-88.
23. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63-9.
24. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354(20): 2103-11.
25. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8(6):215.
26. Lu CH, Wyszomierski SL, Tseng LM, et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res. 2007;13(19):5883-8.
27. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(3):1630-9.
28. Zhuang G, Brantley-Sieders DM, Vaught D, et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 2010;70(1):299-308.
29. US National Institutes of Health. Clinicaltrials.gov Web site. http://clinicaltrials.gov/. Published 2011. Accessed February 9, 2012.
30. Huober J, Loibl S, Untch M. New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer: a translational investigation from the neoadjuvant GeparQuattro study. Presented at: ThirtySecond Annual San Antonio Breast Cancer Symposium; Dec 9-13, 2009; San Antonio, TX.
31. Rosner M, Hengstschlager M. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet. 2008;17(19):2934-48.
32. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008;1(1-4):27-36.
33. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008;7(7):1851-63.
34. Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010;16(2): 205-13.
35. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7(2):e38.
36. Chu R, Zhao X, Griffin C, et al. Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acid. Int J Cancer. 2010;127(5):1209-19.
37. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550-62.
38. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 2011; 13(2):R21.
39. Brunn GJ, Williams J, Sabers C, et al. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996;15(19): 5256-67.
40. Williams R, Berndt A, Miller S, et al. Form and flexibility in phosphoinositide 3-kinases. Biochem Soc Trans. 2009;37(Pt 4):615-26.
41. Maira SM, Stauffer F, Schnell C, et al. PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc Trans. 2009;37(Pt 1):265-72.
42. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009;2:45-54.
43. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9-22.
44. Abu-Khalaf MM, Gettinger SN, Trieu VN, et al. A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P). Presented at: 46th Annual Meeting American Society of Clinical Oncology; Jun 4-8, 2010; Chicago, IL.
45. Rapamune (sirolimus) oral solution and tablets [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc; 2010.
46. Torisel Kit (temsirolimus) injection, for intravenous infusion only [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc; 2010.
47. Afinitor (everolimus) tablets for oral administration [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2012.
48. Yardley DA, Seiler M, Ray-Coquard I. Ridaforolimus (AP23573; MK-8669) in combination with trastuzumab for patients with HER2-positive trastuzumab-refractory metastatic breast cancer: a multicenter phase 2 clinical trial. Presented at: Thirty-Second Annual San Antonio Breast Cancer Symposium; Dec 9-13, 2009; San Antonio, TX.
49. Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004;10(20):7031-42.
50. Jerusalem G, Fasolo A, Dieras V, et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2011;125(2):447-55.
51. Andre F, Campone M, O'Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010;28(34):5110-5.
52. Mayer IA, Burris H, Bendel J, et al. A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. Presented at: Thirty-Second Annual San Antonio Breast Cancer Symposium; Dec 9-13, 2009; San Antonio, TX.
53. Chen CS, Chen MM, Imaoka RT, et al. A phase I pilot study of the oral mTOR inhibitor RAD001 in combination with capecitabine for metastatic breast cancer Presented at: San Antonio Breast Cancer Symposium; Dec 9-13, 2009; San Antonio, TX.
54. Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135-44.
55. Huober J, Hanusch C, Fasching PA, et al. Neoadjuvant chemotherapy of paclitaxel with or without Rad001: results of the non-responder part of the GEPARUINTO study (GBG 44). Presented at: 33rd Annual San Antonio Breast Cancer Symposium; Dec 8-12, 2010; San Antonio, TX.
56. Chow LWC, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Presented at: 29th Annual San Antonio Breast Cancer Symposium; Dec 14-7, 2006; San Antonio, TX.
57. Miller TW, Forbes JT, Shah C, et al. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res. 2009;15(23): 7266-76.
58. Koninki K, Barok M, Tanner M, et al. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett. 2010;294(2):211-9.
59. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S. Hormonal factors and the risk of breast cancer according to estrogenand progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev. 2003;12(10):1053-60.
60. Anderson WF, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76(1):27-36.
61. Fuqua SA. The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2001;6(4):407-17.
62. Anderson WF, Katki HA, Rosenberg PS. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst. 2011;103(18):1397-402.
63. Lee C, Dhillon J, Wang MY, et al. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res. 2008;68(21):8661-6.
64. Tokunaga E, Kimura Y, Mashino K, et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer. 2006;13(2): 137-44.
65. Ghayad SE, Vendrell JA, Ben LS, et al. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010;126(2):545-62.
66. Ghayad SE, Bieche I, Vendrell JA, et al. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008;99(10):1992-2003.
67. Sadler TM, Gavriil M, Annable T, et al. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr Relat Cancer. 2006;13(3): 863-73.
68. Beeram M, Tan QT, Tekmal RR, et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol. 2007;18(8): 1323-8.
69. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005;11(14):5319-28.
70. de Graffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol. 2004; 15(10): 1510-6.
71. Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer. 2008;44:84-91.
72. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6): 520-9.
73. Hortobagyi GN, Piccart M, Rugo H, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO 2 Phase III trial. Presented at: 34th Annual San Antonio Breast Cancer Symposium; Dec 6-10, 2011; San Antonio, TX, USA.
74. Rugo H, Pritchard K, Gnant M, et al. Everolimus (EVE) for postmenopausal women with advanced breast cancer (ABC) refractory to letrozole or anastrozole: long-term efficacy and safety results of the BOLERO-2 trial. Poster presented at: 8th European Breast Cancer Conference; Mar 21-4, 2012; Vienna, Austria.
75. Piccart M, Noguchi S, Pritchard KI, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial 2012. Presented at: 2012 ASCO Annual Meeting; Jun 1-5, 2012; Chicago, IL.
76. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-65.
77. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase 2 trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, HER2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30(22):2718-4.
78. Badin F, Romond E, Chambers M, et al. A phase II trial of fulvestrant and RAD001 (everolimus) in patients with metastatic estrogen receptor positive breast cancer after aromatase inhibitor failure: a study in progress. Presented at: 33rd Annual San Antonio Breast Cancer Symposium, Dec 8-12, 2010; San Antonio, TX, USA.
79. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630-7.
80. Mukohara T, Shimada H, Ogasawara N, et al. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Lett. 2009;282(1):14-24.
81. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26(13):1932-40.
82. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3): 1500-8.
83. Carracedo A, Ma L, Teruya-Feldstein, et al. Inhibition of mTORC1 leads to MAPK pathway feedback activation through a PI3K-dependednt feedback loop in human cancer. J Clin Invest. 2008;118(9):3065-74.
84. Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008; 68(22):9221-30.
85. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008;68(19):8022-30.
86. Liu L, Greger J, Shi H, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009;69(17):6871-8.
87. Chawla SP, Blay J, Ray-Coquard IL, et al. Results of the phase III, placebocontrolled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). Presented at: American Society of Clinical Oncology Annual Meeting; Jun 3-7, 2011; Chicago, IL.